Skip to search formSkip to main contentSkip to account menu

acquired hemophilia

Known as: acquired haemophilia 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2019
Highly Cited
2019
Emicizumab is a recombinant humanized bispecific monoclonal antibody mimicking the cofactor function of activated factor VIII. 
Highly Cited
2016
Highly Cited
2016
We previously showed that pharmacokinetic‐guided prophylaxis (PKP) allows the dosing interval to be extended while maintaining a… 
Highly Cited
2013
Highly Cited
2013
It is essential to improve therapies for controlling excessive bleeding in patients with haemorrhagic disorders. As activated… 
Review
2012
Review
2012
Summary.  Frequent evaluation of haemophilia treatment is necessary to improve patient care. The 2010 Practice Patterns Survey… 
Review
2007
Review
2007
Summary.  The ultimate goal of treatment for patients with inhibitory antibodies should be to permanently eradicate the inhibitor… 
Highly Cited
2005
Highly Cited
2005
Acquired hemophilia (AH) is an extremely rare condition in which autoantibodies (inhibitors) against clotting factor VIII induce… 
Highly Cited
2005
Highly Cited
2005
The safety and efficacy of a full-length sucrose-formulated recombinant factor VIII product (rFVIII-FS; Kogenate FS; Kogenate… 
2003
2003
Abstract: Multicentric Castleman's Disease (MCD) is an atypical lymphoproliferative disorder, related to human herpesvirus 8 (HHV… 
Highly Cited
1998
Highly Cited
1998
Summary. Radiological and orthopaedic outcome in severe and moderate haemophilia A and B patients undergoing long‐term…